Cell & Gene Therapy Products Forum

GBC 4

Cell & Gene Therapy Products Forum

09:00 ~ 18:00 GB III 5F

Summary
Cell and gene therapies have been emerging as a new alternative to treatment of life-threatening and rare incurable diseases with state-of-the-art biotechnologies. We discuss the latest global development including CAR-T, a rapidly emerging form of cancer treatment, and gene therapy, which uses gene editing in order to explore the future direction of our industry.
Date
June 28(Thu), 09:00 ~ 18:00
Venue
GB III 5F Venue Guide

Schedule

Time Title Presentation File
Cell & Gene Therapy Products
Keynote Speech
09:00~09:50(50')

Inteligent surfaces for cell sheet tissue engineering (clinical development)

Teruo Okano / Tokyo Women’s Medical University

[Session1] Clinical Application of Gene Therapy I | Chair : Chae-Ok Yun (Hanyang University)
09:50~10:30(40')

The progress of phase III clinical trial of recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma both in China and US

Wenlin Huang / Sun Yat-sen Universitiy Cancer Center

-
10:30~10:50(20')

Coffee Break

-
10:50~11:30(40')

Clinical Evaluation and Mechanistic Analysis of Retroviral Replicating Vector-mediated Cancer Gene Therapy and Immunotherapy (Phase I-III Clinical Trials)

Noriyuki Kasahara / University of Miami

11:30~12:10(40')

Therapeutic genome editing

Hyongbum Kim / onsei University College of Medicine

12:10~12:50(40')

Targeting Immunotherapy and risk assessment to tumors using oncolytic viruses (Clinical Trial Results)

Stephen J Russell / Mayo Clinic

-
[Session2] Clinical Application of Gene Therapy II | Chair : Stephen J Russell (Mayo Clinic)
14:00~14:40(40')

Combination gene therapy with ultrasound

Joseph Kost / Ben-Gurion University of the Negev Beer-Sheva

14:40~15:20(40')

Long-term follow-up assessment of the safety and efficacy of Invossa-K Inj. for Osteoarthritis

Jae Doo Yoo / Ewha Womans University, Mokdong Hospital

15:20~16:00(40')

Clinical Development and Regulatory Review for LuxturnaTM (voretigene neparvovec-rzyl), First Gene Therapy Approved for a Genetic Disease in the US

Jim Wang / Spark Therapeutics

16:00~16:20(20')

Coffee Break

-
[Session 3] Regulatory Aspects of Gene Therapeutic Products | Chair : Noriyuki Kasahara (University of Miami)
16:20~17:00(40')

Risk Evaluation and Mitigation Strategies (REMS)

Wilson W. Bryan / US FDA

17:00~17:40(40')

Quality Aspects of Gene Therapy Medicinal Products involving Genome Editing Technologies

Silke Schüle / PEI

-